Anzeige
Mehr »
Login
Donnerstag, 20.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Warum der "Fireball" jetzt ein Zündmoment für die Aktie sein könnte!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AE98 ISIN: GB00BYV81293 Ticker-Symbol: 1JS 
Frankfurt
19.01.22
08:10 Uhr
0,480 Euro
-0,004
-0,83 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SHIELD THERAPEUTICS PLC Chart 1 Jahr
5-Tage-Chart
SHIELD THERAPEUTICS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4720,53019.01.
Dow Jones News
203 Leser
Artikel bewerten:
(1)

Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research

DJ Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research 07-Oct-2021 / 09:45 GMT/BST

-----------------------------------------------------------------------------------------------------------------------

Hardman & Co Life Sciences Investor Forum company research:

Shield Therapeutics (STX)

On 23 September we were delighted to host our second Life Sciences Investor Forum. At the live event, Greg Madison, Shield's CEO, answered questions ranging from the performance of Norgine B.V. to the US launch and, in particular, the sales growth of Accrufer(R).

We would like to share with you the research note and slide pack, along with the recording of the presentation.

Read Shield research note | Download Shield slide pack |

Watch Shield forum recording

If you are interested in meeting the company, you can register your interest by clicking here.

To contact us: 
Hardman & Co            Contact: 
1 Frederick's Place 
                  Martin Hall 
London                       mh@hardmanandco.com 
EC2R 8AE 
                  +44 20 3693 7075 
www.hardmanandco.com 
Follow us on Twitter @HardmanandCo 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

-----------------------------------------------------------------------------------------------------------------------

Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

End of Announcement - EQS News Service

1238737 07-Oct-2021

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1238737&application_name=news

(END) Dow Jones Newswires

October 07, 2021 04:45 ET (08:45 GMT)

SHIELD THERAPEUTICS-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.